# Endovascular Treatment of Thoracic Aortic Disease

Study · id `cardio:ct-nct00583817` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT00583817](<https://clinicaltrials.gov/study/NCT00583817>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT00583817

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 170 participants.

## Technical summary

Registry record NCT00583817. Non-randomized; no masking; primary purpose treatment. Start 2018-10-25 (actual); primary completion 2030-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 170 participants (planned count; ClinicalTrials.gov record NCT00583817, source copy `cardio:ctgov-nct00583817-2026-10-22`, retrieved 2026-11-18)
- Started: 2018-10-25 (actual) (ClinicalTrials.gov record NCT00583817, source copy `cardio:ctgov-nct00583817-2026-10-22`, retrieved 2026-11-18)
- Primary completion: 2030-12 (anticipated) (ClinicalTrials.gov record NCT00583817, source copy `cardio:ctgov-nct00583817-2026-10-22`, retrieved 2026-11-18)
- Completion: 2030-12 (anticipated) (ClinicalTrials.gov record NCT00583817, source copy `cardio:ctgov-nct00583817-2026-10-22`, retrieved 2026-11-18)
- Countries: United States (ClinicalTrials.gov record NCT00583817, source copy `cardio:ctgov-nct00583817-2026-10-22`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "ENROLLING\_BY\_INVITATION" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct00583817-2026-10-22`, retrieved 2026-11-18)

## The registry's words

- Brief title: Endovascular Treatment of Thoracic Aortic Disease
- Acronym: EVOLVE Aorta
- Condition: Thoracic Aortic Aneurysms
- Condition: Dissecting, Aneurysm
- Condition: Ascending Aorta Aneurysm
- Condition: Aortic Arch; Aneurysm, Dissecting
- Condition: Ascending Aortic Dissection
- Condition: Thoracoabdominal Aortic Aneurysm
- Condition: Renal Artery Aneurysm
- Condition: Superior Mesenteric Artery Aneurysm
- Condition: Aortic Dissection
- Intervention (Device): Endovascular stent-graft implantation
- Lead sponsor: Matthew Eagleton
- Lead sponsor class: OTHER
- Collaborator: Massachusetts General Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Aortic aneurysm (`cardio:aortic-aneurysm`)
- Registry condition terms include this condition: Aortic dissection (`cardio:aortic-dissection`)
- Registry condition terms include this condition: Thoracic aortic aneurysm (`cardio:thoracic-aortic-aneurysm`)
- Registry lists this organization as a collaborator: Massachusetts General Hospital (`cardio:org-massachusetts-general-hospital`)

## Provenance

Content hash: 459772e9ec08a9fde90c6d69c9f9a1dd621510cb7dbd44d6ac3d1db7332fe190
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
